Table 1.
General Characteristics of the Experimental and Control Group
| Whole cohort (N=220) |
Standard CMR (N=137) |
Tailored CMR (N=83) |
P value | |
|---|---|---|---|---|
| Age, y median [IQR] | 57 [43–70] | 57 [44–68] | 56 [43–73] | 0.987* |
| Male N (%) | 138 (63%) | 89 (65%) | 49 (59%) | 0.378 † , ‡ |
| Scan type N (%): | ||||
| CMR | 151 (69%) | 100 (73%) | 51 (61%) | 0.074 † , ‡ |
| Stress‐CMR | 69 (31%) | 37 (27%) | 32 (39%) | |
| First scan | 212 (96%) | 132 (96%) | 80 (96%) | 1.000 § |
| Follow up scan | 8 (4%) | 5 (4%) | 3 (4%) | |
| Arrhythmia N (13%) | 29 (13%) | 21 (15%) | 8 (10%) | 0.227 † , ‡ |
|
Duration, min, median [IQR] |
39 [31–47] | 45 [39–50] | 30 [27–34] | <0.0001* |
|
CMR, min |
38 [30–46] N=151 |
43 [38–49] N=100 |
28 [24–30] N=51 |
<0.0001* |
|
Stress‐CMR, min |
41 [34–48] N=69 |
48 [42–56] N=37 |
33 [30–36] N=32 |
<0.0001* |
| Quality N (%) | ||||
| Poor | 2 (1%) | 1 (0.73%) | 1 (1%) | 0.842 § |
| Moderate | 53 (24%) | 35 (26%) | 18 (22%) | |
| Good | 164 (75%) | 101 (74%) | 63 (77%) | |
| Primary indication N (%) | ||||
| Cardiomyopathy/myocarditis | 128 (58%) | 86 (63%) | 42 (51%) | 0.169 § |
| Inducible ischemia | 31 (14%) | 17 (12%) | 14 (17%) | |
| Myocardial viability | 12 (5%) | 8 (6%) | 4 (5%) | |
| Research scans | 30 (14%) | 14 (10%) | 16 (19%) | |
| Athlete’s heart | 9 (4%) | 4 (3%) | 5 (6%) | |
| Other | 10 (5%) | 8 (6%) | 2 (2%) | |
| Impact of CMR ‖ N(%) | ||||
| Total (lost to FU) | 190 (44) | 123 (32) | 67 (12) | |
| No. | 146 | 91 | 55 | |
| New diagnosis | 36 (25%) | 20 (22%) | 16 (29%) | |
| New unexpected diagnosis | 1 (<1%) | 0 | 1 (2%) | |
| Therapeutic consequences | ||||
| Change in medication | 20 (14%) | 16 (18%) | 4 (7%) | |
| Invasive procedure/surgery | 27 (18%) | 16 (18%) | 11 (20%) | |
| Ordering of new tests | 3 (2%) | 1 (1%) | 2 (4%) | |
| CMR impact N (%) | 87 (60%) | 53 (58%) | 34 (62%) | |
| Impact of advanced tissue characterization ¶ N (%) |
N=160 (73%) |
N=104 (76%) |
N=56 (67%) |
|
| Increased diagnosis confidence | 73 (45%) | 47 (45%) | 25 (45%) | |
| Unchanged diagnosis confidence | 87 (55%) | 57 (55%) | 31 (55%) | |
Scan duration was calculated from first to last image timestamp. Quality grading: poor (inadequate to answer the clinical question); moderate (presence of artifact not significantly affecting diagnostic performance); good (optimal). Data are expressed as [IQR], N (%), Mean (SD). CMR indicates Cardiac Magnetic Resonance; IQR, Interquartile range; n.s., non‐significant; SD, Standard Deviation; and Stress‐CMR, first‐pass stress perfusion CMR.
Wilcoxon test.
Chi‐square test.
T test.
Fisher test.
Excluding research scans.
Impact of advanced tissue characterization refers to the increase in diagnosis confidence between scans with and without advanced tissue characterization.